Which has higher valuation and earnings, CGEM or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Telix Pharmaceuticals $803.79M 4.74 -$7.12M N/A N/A

Is CGEM or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Telix Pharmaceuticals N/A N/A N/A

Does the media favor CGEM or TLX?

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 11 mentions for Telix Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 0.54 beat Telix Pharmaceuticals' score of -0.06 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CGEM or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is CGEM or CELC more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Celcuity N/A -350.78% -41.54%

Does the media favor CGEM or CELC?

In the previous week, Cullinan Therapeutics had 14 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 5 mentions for Celcuity. Cullinan Therapeutics' average media sentiment score of 0.54 beat Celcuity's score of 0.04 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VKTX or CGEM?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A

Is VKTX or CGEM more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media prefer VKTX or CGEM?

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 11 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.54 beat Cullinan Therapeutics' score of 0.54 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VCYT or CGEM?

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 6 mentions for Veracyte. Cullinan Therapeutics' average media sentiment score of 0.54 beat Veracyte's score of 0.37 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LEGN or CGEM?

In the previous week, Cullinan Therapeutics had 10 more articles in the media than Legend Biotech. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 9 mentions for Legend Biotech. Cullinan Therapeutics' average media sentiment score of 0.54 beat Legend Biotech's score of 0.09 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cullinan Therapeutics (CGEM) Competitors

$15.53 +0.07 (+0.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.52 -0.01 (-0.06%)

As of 10/9/2026 07:30 PM Eastern

Compare

CGEM vs. TLX, CELC, VKTX, VCYT, and LEGN

Should you buy Cullinan Therapeutics stock or one of its competitors? Cullinan Therapeutics's main competitors and comparable companies include Telix Pharmaceuticals (TLX), Celcuity (CELC), Viking Therapeutics (VKTX), Veracyte (VCYT), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 11 mentions for Telix Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 0.54 beat Telix Pharmaceuticals' score of -0.06 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Telix Pharmaceuticals	N/A	N/A	N/A

Cullinan Therapeutics presently has a consensus price target of $33.71, indicating a potential upside of 117.09%. Telix Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 82.87%. Given Cullinan Therapeutics' higher possible upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Cullinan Therapeutics has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market.

86.3% of Cullinan Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Telix Pharmaceuticals	$803.79M	4.74	-$7.12M	N/A	N/A

Summary

Cullinan Therapeutics beats Telix Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Celcuity?

Cullinan Therapeutics (NASDAQ:CGEM) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Cullinan Therapeutics' return on equity of -52.89% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Celcuity	N/A	-350.78%	-41.54%

Cullinan Therapeutics currently has a consensus target price of $33.71, indicating a potential upside of 117.09%. Celcuity has a consensus target price of $154.25, indicating a potential upside of 127.04%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cullinan Therapeutics has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Celcuity is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Cullinan Therapeutics had 14 more articles in the media than Celcuity. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 5 mentions for Celcuity. Cullinan Therapeutics' average media sentiment score of 0.54 beat Celcuity's score of 0.04 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cullinan Therapeutics and Celcuity tied by winning 7 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Viking Therapeutics currently has a consensus price target of $99.44, indicating a potential upside of 248.81%. Cullinan Therapeutics has a consensus price target of $33.71, indicating a potential upside of 117.09%. Given Viking Therapeutics' higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cullinan Therapeutics' return on equity of -52.89% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Viking Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cullinan Therapeutics had 8 more articles in the media than Viking Therapeutics. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 11 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.54 beat Cullinan Therapeutics' score of 0.54 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cullinan Therapeutics beats Viking Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Cullinan Therapeutics' net margin of 0.00%. Veracyte's return on equity of 9.26% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Veracyte has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.03	$66.35M	$1.41	32.08
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Veracyte presently has a consensus target price of $55.78, indicating a potential upside of 23.32%. Cullinan Therapeutics has a consensus target price of $33.71, indicating a potential upside of 117.09%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 6 mentions for Veracyte. Cullinan Therapeutics' average media sentiment score of 0.54 beat Veracyte's score of 0.37 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats Cullinan Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Cullinan Therapeutics (NASDAQ:CGEM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Legend Biotech currently has a consensus price target of $55.50, indicating a potential upside of 198.07%. Cullinan Therapeutics has a consensus price target of $33.71, indicating a potential upside of 117.09%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cullinan Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.51	-$296.80M	-$0.25	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

In the previous week, Cullinan Therapeutics had 10 more articles in the media than Legend Biotech. MarketBeat recorded 19 mentions for Cullinan Therapeutics and 9 mentions for Legend Biotech. Cullinan Therapeutics' average media sentiment score of 0.54 beat Legend Biotech's score of 0.09 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

Legend Biotech has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

Summary

Cullinan Therapeutics beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$994.92M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-5.01	13.42	274.15	26.16
Price / Sales	N/A	1,237.94	590.34	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.24	17.17	11.21	6.34
Net Income	-$219.88M	-$22.69M	$3.50B	$381.90M
7 Day Performance	0.13%	-1.33%	-0.90%	-1.41%
1 Month Performance	-26.05%	-8.44%	-4.44%	-3.48%
1 Year Performance	109.86%	14.02%	6.96%	1.16%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	3.8827 of 5 stars	$15.53 +0.5%	$33.71 +117.1%	+120.3%	$994.92M	N/A	N/A	109	Analyst Upgrade Analyst Revision
TLX Telix Pharmaceuticals	4.3528 of 5 stars	$11.25 -3.1%	$20.50 +82.2%	+11.1%	$3.82B	$803.79M	N/A	1,184
CELC Celcuity	2.951 of 5 stars	$77.92 -2.2%	$154.75 +98.6%	+37.3%	$3.81B	N/A	N/A	155
VKTX Viking Therapeutics	3.7459 of 5 stars	$32.18 -2.6%	$99.67 +209.7%	-18.5%	$3.75B	N/A	N/A	65	Analyst Forecast
VCYT Veracyte	4.0326 of 5 stars	$45.92 +1.5%	$55.78 +21.5%	+29.5%	$3.69B	$517.15M	32.59	755	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TLX, CELC, VKTX, VCYT, and LEGN

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Celcuity?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to Veracyte?

Summary

How does Cullinan Therapeutics compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. TLX, CELC, VKTX, VCYT, and LEGN

How does Cullinan Therapeutics compare to Telix Pharmaceuticals?

Does the media favor CGEM or TLX?

Is CGEM or TLX more profitable?

Do analysts prefer CGEM or TLX?

Which has more risk & volatility, CGEM or TLX?

Do institutionals and insiders hold more shares of CGEM or TLX?

Which has higher valuation and earnings, CGEM or TLX?

Summary

How does Cullinan Therapeutics compare to Celcuity?

Is CGEM or CELC more profitable?

Do analysts recommend CGEM or CELC?

Do institutionals and insiders believe in CGEM or CELC?

Which has more risk and volatility, CGEM or CELC?

Which has stronger earnings and valuation, CGEM or CELC?

Does the media favor CGEM or CELC?

Summary

How does Cullinan Therapeutics compare to Viking Therapeutics?

Which has stronger earnings and valuation, VKTX or CGEM?

Do analysts recommend VKTX or CGEM?

Is VKTX or CGEM more profitable?

Which has more risk & volatility, VKTX or CGEM?

Do institutionals & insiders believe in VKTX or CGEM?

Does the media prefer VKTX or CGEM?

Summary

How does Cullinan Therapeutics compare to Veracyte?

Which has more volatility & risk, VCYT or CGEM?

Is VCYT or CGEM more profitable?

Do institutionals and insiders believe in VCYT or CGEM?

Which has better valuation and earnings, VCYT or CGEM?

Do analysts recommend VCYT or CGEM?

Does the media prefer VCYT or CGEM?

Summary

How does Cullinan Therapeutics compare to Legend Biotech?

Do analysts recommend LEGN or CGEM?

Which has higher earnings & valuation, LEGN or CGEM?

Does the media prefer LEGN or CGEM?

Do institutionals & insiders believe in LEGN or CGEM?

Is LEGN or CGEM more profitable?

Which has more risk and volatility, LEGN or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools